USP22 and neoplasm: One of these tumor intrinsic epigenetic factors in PDAC is ubiquitin-specific protease 22 (USP22), which is suggested to control the immune TME through transcriptional regulation; thus, future inhibition of USP22 may turn the tumor sensitive to ICI [61].